

# 1 Underlying co morbidity reveals unique immune signatures 2 in Type II diabetes patients infected with SARS-CoV2

3 Soumya Sengupta<sup>1,2†</sup>, Gargee Bhattacharya<sup>1,2†</sup>, Sanchari Chatterjee<sup>1,2</sup>, Ankita Datey<sup>1,3</sup>,  
4 Shubham K Shaw<sup>1,2</sup>, Sandhya Suranjika<sup>1</sup>, Paritosh Nath<sup>1</sup>, Prakash K Barik<sup>1</sup>, Punit Prasad<sup>1,2</sup>,  
5 Soma Chattopadhyay<sup>1,2</sup>, Rajeeb K Swain<sup>1,2\*</sup>, Ajay Parida<sup>1,2\*</sup>, Satish Devadas<sup>1,2\*</sup>

6 1 Institute of Life Science, Nalco Square, Bhubaneswar, Odisha, India-751023.

7 2 Regional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, Haryana-121001,  
8 India

9 3 School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) University,  
10 Bhubaneswar, Odisha, India-751024.

11 †These authors contributed equally

12 \*Address of Corresponding authors:

13 Dr Rajeeb K Swain (RS)

14 Cancer Biology,

15 Institute of Life Sciences

16 (Autonomous Institute of Dept of Biotechnology, Govt. of India),

17 Nalco Square, Bhubaneswar-751023. Odisha, India

18 Phone No: 0091 0674 2304 301, Fax No: 0091 674 2300728

19 E-mail: [rkswain@ils.res.in](mailto:rkswain@ils.res.in)

20 Dr. Ajay Parida (AP)

21 Plant and Microbial Biotechnology,

22 Institute of Life Sciences,

23 (Autonomous Institute of Dept of Biotechnology, Govt. of India),

24 Nalco Square, Bhubaneswar-751023. Odisha, India

25 Phone No: 0091 674 2304324; Fax No: 0091 674 2300728

26 E-mail: [drajayparida@gmail.com](mailto:drajayparida@gmail.com), [ajayparida@ils.res.in](mailto:ajayparida@ils.res.in)

27 Dr. Satish Devadas (SD)

28 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**  
Infectious Disease Biology,

- 29 Institute of Life Sciences Institute of Life Sciences,  
30 (Autonomous Institute of Dept of Biotechnology, Govt. of India),  
31 Nalco Square, Bhubaneswar-751023. Odisha, India  
32 Phone No: 0091 674 2300701; Fax No: 0091 674 2300728 E-mail: [satdevs@ils.res.in](mailto:satdevs@ils.res.in)

## 33 Abstract

34 **Background:** SARS-CoV2 infection in patients with comorbidities, particularly T2DM has  
35 been a major challenge globally. Here, we did whole blood immunophenotyping along with  
36 plasma cytokine, chemokine, antibody isotyping and viral load determination from  
37 oropharyngeal swab to understand the immune pathology in the T2DM patients infected with  
38 SARS-CoV2.

39 **Methods:** Blood samples from 25 Covid-19 positive patients having T2DM, 10 Covid-19  
40 positive patients not having T2DM and 10 Covid-19 negative, non-diabetic healthy controls  
41 were assessed for various immune cells by analyzing for their signature surface proteins in  
42 mass cytometry. Circulating cytokines, chemokines and antibody isotypes were determined  
43 from plasma. Viral copy number was determined from oropharyngeal swabs. All our  
44 representative data corroborated with laboratory findings.

45 **Results:** Our observations encompass T2DM patients having elevated levels of both type I and  
46 type II cytokines and higher levels of circulating IgA, IgM, IgG1 and IgG2 as compared to  
47 NDM and healthy volunteers. They also displayed higher percentages of granulocytes, mDCs,  
48 plasmablasts, Th2-like cells, CD4<sup>+</sup> EM cells, CD8<sup>+</sup> TE cells as compared to healthy volunteers.  
49 T2DM patients also displayed lower percentages of pDCs, lymphocytes, CD8<sup>+</sup> TE cells, CD4<sup>+</sup>,  
50 CD8<sup>+</sup> EM.

51 **Conclusion:** Our study demonstrated that patients with T2DM displayed higher inflammatory  
52 markers and a dysregulated anti-viral and anti-inflammatory response when compared to NDM  
53 and healthy controls.

54 **Contribution to the field:** Covid-19 infection in people with comorbidities, particularly  
55 T2DM has been a cause of mortality in several nations and they represent an extremely  
56 vulnerable population to Covid-19. This study is one of the most comprehensive study from  
57 India, to understand the interplay between immune response and viremia occurring in these  
58 T2DM patients infected with SARS-CoV2 and will help in designing public health response  
59 and vaccination priorities.

60 **Keywords-** SARS-CoV2, Type II Diabetes, Whole blood Immunophenotyping, Innate  
61 Immune Response, Adaptive Immune Response

62

## 63 Introduction

64 Since the outbreak of the novel coronavirus disease (Covid-19) in late 2019, India has  
65 recorded over 34 million cases and 4,54,745 deaths as of 25<sup>th</sup> October, 2021 and now has the  
66 second highest number of cases in the world, after the United States of America. Essentially,  
67 SARS-Cov2 is a betacoronavirus, belonging to Coronaviridae family and is closely related to  
68 SARS and MERS, which were responsible for earlier disease outbreaks in 2003 and 2011  
69 respectively(1). Broadly, Covid-19 cases were and are still classified into symptomatic and  
70 asymptomatic, based on the presence or absence of symptoms and eventual severity based on  
71 immune response and/or its failure. With respect to the symptoms of Covid-19 infection,  
72 symptomatic patients have fever, dry cough, shortness of breath, acute respiratory distress, loss  
73 of taste and smell and in certain cases diarrhoea (2, 3). Based on the intensity of these  
74 symptoms, the patients are classified into mild and severe, during diagnosis. Prognosis of the  
75 severe patients is critical. However, the major challenge arises from the huge population of  
76 asymptomatic cases, as they are responsible for the undetected spread of infection.

77 In general, disease severity in Covid-19 is associated with lymphopenia, cytokine  
78 storm, blood coagulation, drop in pO<sub>2</sub> levels, etc. (4, 5). However, with respect to the Indian  
79 population, these clinical parameters and the associated immune response were not definitely  
80 present in most Covid-19 infected patients. Interestingly, one of the major attributes of Covid-  
81 19 in Indian population, especially in the first wave, was quick recovery, but the underlying  
82 immunological mechanism was and is yet to be understood. However, similar to the first wave,  
83 70% of India's mortality in Covid-19 in the second wave is still attributed to comorbidities,  
84 specifically type II diabetes (T2DM). Although vaccinations drive initiated by the government  
85 aims to protect the population in general, the overwhelming number of these patients poses a  
86 major challenge to recovery and recuperation of the individual. In that respect, co-relation  
87 between comorbidities including T2DM and viral load, T2DM and glucose levels, etc. in the  
88 patient can play a major role in dictating the immune response and eventual outcome of Covid-  
89 19 infection. Therefore, it is crucial to understand the interplay of these factors along with  
90 immunological parameters to give us a comprehensive idea about the status of T2DM patients  
91 having Covid-19.

92 Immune response can be divided into three types namely, type I (antiviral), type II (anti  
93 helminthic), type III (antifungal). Type I response mainly constitutes of T-bet and Interferon  
94 gamma (IFN- $\gamma$ ) mediated response, which is against intracellular pathogens, including viruses.

95 On the other hand, type II response is mediated by GATA-3 and is mainly against helminthic  
96 worms, which are carried out by effector molecules such as IL-4, IL-9, and IgE. The third type  
97 of response (type III response) is mediated by ROR- $\gamma$ t and effector molecules such as IL-17A,  
98 IL-17F, IL-22 etc. are responsible for controlling fungal infections (6, 7). Longitudinal  
99 analysis has shown an immune dysregulation in Covid-19 patients and people with T2DM  
100 contracting Covid-19 Infection had higher innate immune cells, lower T lymphocytes, a  
101 sustained increase in antiviral, anti-fungal response and higher type 2 response such as IL-5,  
102 IL-13, IgE and eosinophils (8).

103 Altogether, the immunological response in Covid-19 patients with co-morbidity is an  
104 evolving area of study and these patients represents higher vulnerability in comparison to the  
105 ones without any comorbidity or other comorbidities. Our study aims to elucidate the  
106 differences between T2DM patients having Covid-19 as compared to those devoid of T2DM,  
107 based on multiple parameters such as viral load, cytokine *milieu* and immune cells, which will  
108 give us a comprehensive idea about the role played by T2DM in Covid-19 pathogenesis.

109

## 110 **Materials and Methods**

### 111 **Population and Samples**

112 A total of 25 samples with T2DM and 10 samples without T2DM (NDM) (Non-diabetes  
113 mellitus) were collected. These samples were collected from hospital within 4 days of patient's  
114 admission. Type II diabetes in these patients was confirmed by previous clinical history and  
115 for this particular study was assessed by fasting plasma glucose level and glycated haemoglobin  
116 and other clinical and biochemical parameters as requested by their consultant medical  
117 practitioner. Amongst these, 22 patients with T2DM had hypertension. The T2DM or NDM  
118 patients neither reported nor were assessed for other comorbidities during the infection. The  
119 detailed laboratory findings are given in Table 1. All the T2DM patients had severe symptoms,  
120 as assessed by the clinician. The NDM patients either had mild symptoms or were  
121 asymptomatic. Additionally, 10 healthy volunteers who tested negative for Covid-19 were  
122 included in the study to provide basal and or steady state biochemical and cytokine profile.  
123 Briefly, 5ml blood was collected in BD Vacutainer EDTA tubes (BD 367863) and 270 µl of  
124 whole blood from 10 T2DM patients, 5 NDM patients and 5 healthy volunteers was used for  
125 deep immune profiling by mass cytometry. The tubes were spun at 1600g for 20 minutes at  
126 room temperature. Plasma was then collected and stored in -80 °C till further analysis. The  
127 details of all the reagents and software used are given in the supplementary table 1 (S1).

### 128 **SARS-CoV2 Viral load detection in respiratory specimen and plasma**

129 300 µl each of oropharyngeal swab and plasma were taken for viral RNA extraction  
130 using TAN Bead Maelstrom 4800 as per manufacturer's instructions. The extracted viral RNA  
131 was stored at -80°C until further use (9).

### 132 **qRT-PCR**

133 The qRT-PCR was performed using 5µl of the extracted RNA from samples using the  
134 TRUPCR SARS-CoV-2 RT qPCR Kit V-2.0. The human RNase P served as an internal control  
135 whereas envelope (E) and nucleocapsid (N) genes were targeted for SARS-CoV-2  
136 amplification (9).

### 137 **Viral copy number determination**

138 The viral copy number was determined for the above-mentioned samples by generating  
139 the standard curve of SARS CoV-2 N (nucleocapsid) gene. The N gene was cloned into pBiEx  
140 vector and 10-fold serial dilutions of the plasmid were done to obtain the standard curve. The

141 percentage of copy number/ml was calculated from the corresponding Ct values of all the  
142 samples. For obtaining Ct values, cDNA was prepared from the extracted RNA using random  
143 hexamers by TAKARA primescript 1st strand cDNA synthesis kit (Kusatsu, Japan). The  
144 cDNA was subjected to qPCR (Mesagreen SYBR Green-No ROX, Eurogentec, Belgium)  
145 using nucleocapsid gene specific primers. (FP: GTAACACAAGCTTTTCGGCAG and RP:  
146 GTGTGACTTCCATGCCAATG) (9).

#### 147 **Plasma Cytokine and Chemokine detection assay**

148 Neat plasma from Covid-19 and controls was used to measure 41 cytokines and  
149 chemokines using human Milliplex map cytokine assay kit (Millipore, Billerica, MA, USA).  
150 The samples were acquired in a Bio-Plex 200 system (Bio-Rad, Hercules, CA, USA) and  
151 cytokine concentrations were calculated using Bio-Plex manager software with a five-  
152 parameter (5PL) curve-fitting algorithm applied for standard curve calculation (10).

#### 153 **Isotyping of circulating antibody from blood**

154 For analysis of the isotype composition of antibodies in circulation, plasma of T2DM,  
155 NDM patients and healthy volunteers, were analysed by ProcartaPlex Human Antibody  
156 Isotyping Panels (Cat. No EPX070-10818-901, Invitrogen, Vienna, Austria), based on the  
157 manufacturer's instructions. Briefly, antibody-coated magnetic bead mixtures were incubated  
158 with 25µl of assay buffer, kit standards or diluted plasma (1:20000) samples in a ProcartaPlex  
159 96-wells plate at room temperature for 1 hour. Detection antibodies (25 µl) were then added  
160 and the plates were incubated on an orbital shaker at 500 rpm for 30 min. Next, the wells were  
161 incubated with 50µl of diluted Streptavidin-Phycoerythrin for 30 min. Plates were then washed  
162 using a hand-held magnetic plate washer. All incubations were performed at room temperature  
163 in the dark. Afterwards, samples were suspended in 120 µl reading buffer. The samples were  
164 acquired in a Bio-Plex 200 system (Bio-Rad, Hercules, CA, USA) and cytokine concentrations  
165 were calculated using Bio-Plex manager software with a five-parameter curve-fitting algorithm  
166 (5PL) applied for standard curve calculation (11).

#### 167 **Whole blood Immunophenotyping by Mass Cytometry**

168 For immunophenotyping, 270µl of whole blood was collected, added to pre-coated  
169 Maxpar Direct Immune Profiling tubes and incubated for 30 minutes in room temperature. For  
170 lysis, 250µl of 1x BD FACs Lyse was added, followed by 10 min incubation. There were two  
171 consecutive washes with Maxpar water and Cell staining buffer. The cells were then fixed

172 with 4% formaldehyde and incubated for 10 minutes followed by washing at 800g for 5  
173 minutes. Eventually, the cells were suspended in 1ml Iridium solution and stored in -80 °C till  
174 acquisition. For acquisition, the cells were thawed, washed with Cell Staining buffer and Cell  
175 Acquisition Solution. The cell density was adjusted to 1 million cells/ml in Cell acquisition  
176 Solution with 0.1% EQ Beads and acquired in Helios Mass cytometer. FCS files were then  
177 normalised with CyTOF software V.7 (Fluidigm) and then exported and analysed by FlowJo  
178 software V10.7 (BD Biosciences)(12, 13).

## 179 **Statistics**

180 Statistical analysis was performed using the GraphPad Prism software, version 8.0.1.  
181 Data was presented as Mean  $\pm$  Standard Deviation of Mean (SEM). Non-parametric Kruskal  
182 Wallis Test with post hoc Dunn's multiple comparison test was used to compare the levels of  
183 cytokines, antibodies and percentage of different immune cells among the three groups. Mann-  
184 Whitney U test was used to compare laboratory parameters between T2D and NDM patients.  
185 *P* values less than 0.05 were considered significant (\**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001,  
186 \*\*\*\**P* < 0.0001).

## 187 **High dimensional analysis**

188 For high dimensional analysis, t-SNE analysis was performed using FlowJo V.10.7 (BD  
189 Biosciences). The gating for analysis was done on live, intact, CD45<sup>high</sup>CD66b<sup>low</sup> lymphocytes.  
190 Amongst a total of 100,000 events, 5000 events in the lymphocyte population were used per  
191 sample for this analysis. 5 samples of T2D and of Healthy controls were used to compute t-  
192 SNE and a total of 25000 events per group were concatenated and exported for t-SNE analysis.  
193 The default parameters in the software, iterations-1000, perplexity-30, eta-675, KNN  
194 algorithm-Exact (vantage point tree), gradient logarithm-Barnes-Hut were used to compute the  
195 t-SNE plot.

## 196 **Ethics Statement**

197 The studies involving human participants were reviewed and approved by the  
198 Institutional Human Ethics Committee, Institute of Life Sciences. The Institutional Ethics  
199 Committee (IEC)/ Institutional Review Board (IRB) reference number is 106/HEC/2021.  
200 Written consent informed to participate in this study was provided by the participants'  
201 spouse/next of kin.

## 202 **Data Availability Statement**



203           The human clinical data is stored at KIMS Hospital, samples are stored at ILS  
204 Biorepository, Ethical clearance with the corresponding authors and on request for this, ethical,  
205 legal, and privacy consent will be requested from both the doctor and patient to share data.

## 206 **Author Contributions**

207 Experimental Design and Conceptualization – SD, SS and GB

208 Sample Collection and processing- RS, PP, SaS, SS, GB, SaC, PB and PN

209 Mass Cytometry Experiments- SS, GB and SKS

210 Chemokine and Cytokine Multiplexing- SS, SaC and GB

211 Antibody Isotyping- SS, SaC and AD

212 RT-PCR and Virological assays- SaC, AD and SC

213 Data analysis- SS, GB, SaC, AD, SC and SD

214 Manuscript Drafting- SS, GB, SaC, SC and SD

215 Manuscript Editing and Review- GB, SS, RS, PP, AP, SC and SD

## 216 **Conflict of Interest.**

217           The authors declare no conflict of interest. The funding agency had no role in the design  
218 of the study; in the collection, analyses, or interpretation of data; in the writing of the  
219 manuscript, or in the decision to publish the results.

## 220 **Funding.**

221           This study was supported by the core funding of Institute of Life Sciences,  
222 Bhubaneswar, Dept of Biotechnology, India. SS was funded by the DBT fellowship. GB, SaC  
223 and SKS were funded by the CSIR fellowship.

## 224 **Acknowledgements.**

225           We would like to acknowledge ILS Biorepository for providing the SARS-CoV2  
226 samples. We would like to thank Dr. Gajendra Motiram Jogdand for valuable suggestions in  
227 multiplexing. We would also like to thank Mr. Deepak Singh, Mr. Satyajit Behera and Ms.  
228 Jyotsna Priyadarshini for data entry.

## 229 **Results**

### 230 *Viral load does not corroborate with inflammation in T2DM*

231 The study was executed on NDM and T2DM Covid-19 patients, who had been detected  
232 and admitted to a local tertiary COVID hospital. To examine for viral load, oropharyngeal  
233 (OP) samples were collected from various patients as per established protocol and processed  
234 in the BSL3 facility at ILS, Bhubaneswar. In most of the NDM and T2DM patients, there was  
235 no significant difference in the viral copy number or  $\Delta\Delta$  Ct values of OP samples at the time  
236 of sampling (**Fig. 1A and B**). This suggests that the viral load in OP samples does not and did  
237 not correlate with disease severity in this population of study. This probably indicates that the  
238 viral load present in the host does not dictate the severity of Covid-19 infection.

### 239 *Altered cytokine and chemokine profiles in Covid-19 patients with Type II Diabetes*

240 To investigate the status of systemic inflammation concurrent with SARS-Cov2  
241 infection, we did multiplexing analysis of 41 cytokines and chemokines from the plasma of  
242 T2DM and NDM patients to delineate the altered immune microenvironment in these patients.  
243 For comparison and for basal level expression of these cytokines and chemokines, we added  
244 ten healthy volunteers and segregated the proteins into significant, moderate and mild based on  
245 the level of their expression in T2DM as compared to NDM and healthy volunteers.  
246 Accordingly, the levels of IL-6, TNF- $\alpha$ , G-CSF, GM-CSF, IFN- $\alpha$ 2, IL-10, VEGF, IL-1R $\alpha$ , IL-  
247 12p40, IL-15, IL-1 $\alpha$ , MIP-1 $\beta$ , were found to be significantly elevated ( $p < 0.0001$ , Kruskal  
248 Wallis Test), indicating the simultaneous release of both Type I and Type II cytokines in  
249 severity (**Fig. 2A**). In contrast, there was moderate elevation in the levels of IFN- $\gamma$ , EGF, IL-  
250 8, indicative of the ongoing antiviral reaction in these patients (**Fig. 2B**). Amongst the slightly  
251 elevated ones, IP-10 ( $p = 0.0365$ ), IL-9, IL-4 ( $p = 0.0146$ ) showed higher significance (**Fig. 2C**).  
252 Although IP-10 has been used as a real time marker for mortality in Covid-19 patients, we did  
253 not do a longitudinal patient tracking, therefore cannot ascertain its role in mortality. In  
254 addition, IL-4 and IL-9 which are both type II cytokines have also been linked to severity of  
255 Covid-19 patients. Although our study could not find any significant difference in levels of  
256 type III signature cytokines such as IL-17 and IL-1 $\beta$ , the presence of type I and type II immune  
257 signatures were overlapping in multiple patients (data not shown). However T2DM patients  
258 showed elevation of both type I and type II cytokines indicating a dysregulated immune  
259 response, prominent in these patients as earlier reported by Lucas et al (**Fig. 2**).

260 Interestingly, the levels of chemokines as opposed to cytokines, were higher in NDM  
261 and healthy volunteers as opposed to T2DM patients. For example, the levels of Eotaxin were  
262 found to be lower in T2DM than in NDM patients and healthy controls (**Fig 2D**). In general,  
263 Eotaxin is associated with chemoattraction of eosinophils, basophils and neutrophils. Previous  
264 studies have reported its increase with severity but in our study, the population indicated a  
265 reverse trend; decreasing Eotaxin levels in the T2DM patients. This can be indicative of an  
266 impaired healing process as previous reports have suggested a positive correlation between  
267 increasing number of eosinophils and healing. In addition, sCD40L was elevated in NDM  
268 patients as compared to T2DM and healthy volunteers (**Fig. 2E**). Since sCD40L has been  
269 associated with immunosuppression, it is indicative of an anti-inflammatory immune response  
270 in NDM patients, which is clearly absent in T2DM cases. Similarly, the levels of MDC  
271 (macrophage derived chemokine) were also higher in NDM as compared to T2DM patients,  
272 demonstrating its potential role in immune suppression (**Fig. 2E**). In addition, GRO levels  
273 were higher in both NDM and T2DM patients as compared to healthy controls (**Fig. 2F**). As  
274 GRO serves as a chemoattractant for neutrophils, it is indirectly indicative of the status of  
275 underlying inflammation in NDM and T2DM patients. Collectively, our cytokine and  
276 chemokine profile of T2DM patients showed an increasing trend in the inflammatory cytokine  
277 panel and augmented levels of chemokines that were primarily responsible for repair and  
278 angiogenesis.

### 279 *Circulating antibody isotype profiling showed a skewed inflammatory profile in Covid-19* 280 *patients with Type II Diabetes*

281 Various antibody isotypes correlate with the clinical phenotype of an infection and is  
282 therefore an important indicator of the type of immune response. Since cytokine *milieu* in  
283 T2DM and NDM patients was skewed, we wanted to define the circulating antibody isotypes  
284 in these patients as opposed to healthy controls. We did Luminex based multi plex assay from  
285 their plasma and quantified the amount of IgA, IgM, IgE, IgG1, IgG2, IgG3 and IgG4. Here,  
286 we found IgG1 and IgG2 to be significantly elevated in T2DM patients as compared to healthy  
287 controls ( $p < 0.0001$ ) and NDM patients ( $p = 0.0024$  for IgG1 and  $p = 0.0033$  for IgG2),  
288 correlating with the higher levels of type I cytokines in these patients. IgE, being a hallmark  
289 of type II immune response was also elevated in T2DM as compared to NDM ( $p = 0.0453$ ) and  
290 healthy control ( $p = 0.0347$ ). Alongside, IgA being associated with mucosal immunity was also  
291 higher in T2DM patients as compared to NDM ( $p = 0.0012$ ) and healthy controls ( $p = 0.0140$ ).  
292 As IgM is the first antibody isotype to appear during the course of infection, accordingly we

293 found its levels to be higher in T2DM patients as compared to NDM ( $p=0.0178$ ) and healthy  
294 controls ( $p=0.0017$ ) (**Fig. 3**). In summary, the antibody isotype profile was concurrent to the  
295 cytokine levels, thus confirming and furthering the status of disease severity in Covid-19  
296 patients.

### 297 *Dysregulated innate immune system in Covid-19 patients with Type II Diabetes*

298 With the cytokine multiplexing and antibody isotyping indicating an altered immune  
299 response, our next objective was to delineate the alteration in the cells of innate and adaptive  
300 immune system during Covid-19. Based on the surface markers analysed, we found T2DM  
301 patients showing significant increase in  $CD45^{low}CD66b^{high}$  granulocytes as compared to  
302 healthy controls ( $p=0.0074$ ), which is concurrent with the increase in the levels of IL-8 (**Fig.**  
303 **4A**). The bulk population of these granulocytes were neutrophils, though we did not find any  
304 significant difference between the levels of neutrophils in T2DM, NDM and healthy controls  
305 (data not shown). Also, dendritic cell populations were variable, with their numbers decreasing  
306 in T2DM as compared to NDM and healthy controls (**Fig. 4B**). This was in contrast to the  
307 increase in IFN- $\alpha 2$  levels, indicating towards dysregulated dendritic cell population in T2DM  
308 patients (**Fig. 2A**). Within the dendritic cell population, plasmacytoid dendritic cells (pDCs)  
309 decreased in T2DM patients as compared to NDM and healthy controls (**Fig. 4B**). However,  
310 percentage of myeloid dendritic cells (mDCs) increased in T2DM patients as compared to  
311 NDM and healthy controls (**Fig. 4C**). The percentage of basophils was also reduced in T2DM  
312 patients as compared to healthy volunteers, which was correlating with the decrease in levels  
313 of chemokine, Eotaxin (CCL11) (**Fig. 4D**). Although, we did not observe any variation  
314 between T2DM, NDM and healthy controls in the populations of gamma delta cells and natural  
315 killer cells there was reduction in the percentage of MAIT/NKT cells in T2DM patients as  
316 compared to healthy and NDM patients (**Fig. 4E**). As reported earlier (data not shown), there  
317 were no changes in the overall or subsets of monocytes and natural killer cells. Altogether,  
318 alterations in the innate immune cell population is suggestive of an aberrant immune response  
319 incapable of controlling the infection.

### 320 *Heterogenicity in Lymphocyte population in Covid-19 patients with Type II Diabetes, NDM* 321 *and healthy controls*

322 Lymphocytes are instrumental in fighting infections and earlier reports indicated  
323 towards its decreasing trend in T2DM patients. There was a moderate decrease in the  
324 percentage of lymphocyte in T2DM as compared as to the healthy controls (**Fig. 4A**). Amongst

325 lymphocytes, percentage of total B cell population was expanding in T2DM patients as  
326 compared to healthy controls (**Fig. 5A**) and was is in direct correlation with increased IgG1  
327 and IgG2 in the former (**Fig. 3**). Further analyses revealed a significant increase in plasmablast  
328 population in T2DM patients as compared to healthy controls. Additionally, we found a  
329 significant decrease in the percentage of CD3<sup>+</sup> T cells in T2DM patients as compared to healthy  
330 controls suggesting lymphopenia associated with increased severity (**Fig. 5B**). Within the T  
331 cell population, there was an increase in the percentage CD4<sup>+</sup> T cells (statistically insignificant)  
332 but decrease of CD8<sup>+</sup> T cells (**Fig. 5B**). Further, in depth analysis of CD4<sup>+</sup> T cells revealed  
333 that T2DM patients had an increase of the Th2 subtype as compared to NDM or healthy  
334 volunteers (**Fig. 5C**). This can be correlated with the increased levels of IL-4 and IL-9, found  
335 in the plasma of these patients (**Fig. 2C**). However, Th1, Th17, Treg and Tfh cells did not  
336 show any statistically significant difference, which can be attributed to the time of sampling or  
337 be a consequence of dysregulated immune response. There was also no significant difference  
338 in Naïve CD4<sup>+</sup> T cells or Central memory CD4<sup>+</sup> T cells within the groups. But terminal effector  
339 (TE) cells were decreased and effector memory (EM) cells were increased in T2DM patients  
340 as compared to healthy controls (**Fig. 5D**). This was in contrast to the CD8<sup>+</sup> compartment,  
341 where TE cells were increased in T2DM patients as compared to NDM but there was no  
342 difference between T2DM and healthy controls suggesting a robust response in NDM patients  
343 as compared to T2DM and a certain degree of cross-reactive reaction occurring in these T2DM  
344 patients (**Fig. 5E**). Similarly, there was significant decrease of EM cells in T2DM as compared  
345 to NDM while no difference was observed in healthy controls when compared to T2DM or  
346 NDM. Collectively, a bias was found towards terminal effector CD8<sup>+</sup> T cells in T cell immune  
347 response which was suggestive of an effective ongoing anti-viral response.

#### 348 ***High Dimensional analysis reveals immune perturbations in T2DM patients***

349 We also performed t-distribution stochastic neighbour embedding (t-SNE) analysis to  
350 understand how different markers reported previously, show variability in Covid-19 patients  
351 in our population of study. t-SNE analysis revealed a decrease in the expression of CD3 and  
352 CD8 in T2DM patients as compared to healthy volunteers (**Fig. 6A**). On the contrary, there  
353 was increase in the expression of CD14, CD38 and HLA-DR in T2DM patients as compared  
354 to healthy volunteers (**Fig. 6B**).

## 355 Discussion

356 The Covid-19 pandemic has brought an unprecedented global devastation on lives and  
357 livelihood of the common people, breakdown of the best healthcare system and economic  
358 collapse all across the globe. Till October 2021, India reported around 34 million cases, being  
359 second in place to the United States of America. Unfortunately, a bulk population of Covid-  
360 19 cases in India who had succumbed to the infection had comorbidities and amongst these,  
361 Type II Diabetes was the most common. At present, there are no significant reports from India  
362 providing an insight into the variations in immune response, extent of inflammation and  
363 outcome in T2DM patients as compared to NDM patients and healthy volunteers. In this study,  
364 we attempted to describe and compare immune response, viral loads and clinical parameters  
365 amongst T2DM, NDM and healthy volunteers. In that respect, 25 patients with T2DM, 10  
366 NDM patients and 10 healthy volunteers were studied for cytokine, chemokine, viral loads,  
367 clinical parameters and antibody isotyping assays for understanding the immunopathology of  
368 the virus. Ten T2DM, five NDM and five healthy volunteers were studied for whole blood  
369 mass cytometry assay to determine the difference in immune cells amongst the groups. While  
370 it is understood that this is a very small group, some clear patterns are established here  
371 suggesting that the chronic Meta inflammation in Type II Diabetes might play a role in further  
372 precipitating the inflammatory signatures in Covid-19.

373 It is known that mild inflammation serves as one of the major initiator mechanisms of  
374 the immune system that is extremely crucial in fighting infection (14). However elevated levels  
375 of circulatory cytokines and eventual cytokine storm and dysregulated inflammatory responses  
376 have been evinced in Covid-19 infection (2, 4). Additionally, previous reports suggest that  
377 patients with T2DM have a higher vulnerability for SARS-CoV2 infection (15, 16) where  
378 persistent low grade inflammation associated with T2DM was evinced but not co related to be  
379 causal. Our data taken together with biochemical, cytokine and antibody profile strongly  
380 indicate that chronic low grade inflammation and the consequential dysregulated immune  
381 response might be responsible for the upsurge of inflammatory responses in Covid-19 patients  
382 leading to severe infection and or mortality.

383 Our preliminary objective in the study was to assess the differences in viremia in  
384 Oropharyngeal swab between the two groups. However, viral load of OP samples did not show  
385 any significant difference between the two groups. This was in accordance with previous  
386 studies, where it was observed that the viral load in nasal and throat swab samples were similar

387 in the NDM and T2DM patients (17, 18). Here, the T2DM are considered as severe Covid-19  
388 patients, based on the severity of their symptoms. And, the NDM patients either had NDM  
389 symptoms (n=4) or were asymptomatic (n=6). This is evident from the clinical parameters as  
390 T2DM patients had higher levels of CRP which is a non-specific inflammatory marker,  
391 dysregulated glucose metabolism as evident from higher plasma glucose, glycated  
392 haemoglobin and impaired blood coagulation as interpreted from higher d-dimer levels(19-22).

393 Cytokines and chemokines are soluble mediators that control the migration of immune  
394 cells to the site of inflammation, providing a pro or anti-inflammatory environment which  
395 essentially shapes the type of immune response during a disease. In our T2DM patients who  
396 were infected with SARS-CoV2, higher expression of both type I and type II cytokines were  
397 evinced. Previous reports suggest the involvement of both the types of cytokines in aggravating  
398 the severity of the disease. Increase in type I cytokines such as IFN- $\gamma$  TNF- $\alpha$ , IFN- $\alpha$ 2, IL-6,  
399 GMCSF, IL-8 indicated a robust antiviral and inflammatory response occurring in these T2DM  
400 patients. Additionally, these patients also showed an increase in type II cytokines such as IL-4  
401 and IL-9, representing the anti-inflammatory response. Here, we understand that the presence  
402 of both inflammatory and anti-inflammatory cytokines in T2DM patients as indicators of a  
403 dysregulated immune response where the anti-inflammatory response was clearly incapable of  
404 shutting the cytokine storm in these patients(23).

405 In diabetic patients, there is an increase in the inflammatory cytokines, CRP levels and  
406 the presence of blood clots. As similar symptoms are associated with Covid-19 i.e. elevated  
407 CRP levels, D-dimer and inflammatory cytokines, this suggests towards a synergistic effect  
408 found in T2DM patients infected with SARS-Cov2, which was reduced in NDM patients.  
409 Additionally, our study suggested an increase in IL-15 and 1L-7 in T2DM patients when  
410 compared to NDM and healthy volunteers. As it is known that IL-15 is crucial for promoting  
411 cytotoxic activity of both, NK and CD8<sup>+</sup> T cells and is also involved in memory CD8<sup>+</sup> T cell  
412 differentiation, it should have led to increase in the CD8<sup>+</sup> population(24). However, we found  
413 a decrease in the CD8<sup>+</sup> cell population, specifically in the EM compartment, again indicating  
414 a dysregulated or non-responsive immune response in these patients. This might be a  
415 consequence of reduced receptors for IL-15 in these cells. As IL-7 is also required for T cell  
416 development and maintenance(25), its increased numbers in T2DM patients partially  
417 corroborated with the increase in CD8<sup>+</sup> TE cells and CD4<sup>+</sup> EM cells. However, as a  
418 consequence of immune dysregulation, neither the elevated levels of the above mentioned  
419 cytokines nor the CD8<sup>+</sup> T cells, are capable of controlling the inflammation.

420 The sCD40L is one of the major co-stimulatory molecules on activated T cells that  
421 interact with CD40 on B cells and is responsible for immunoglobulin isotype switching in the  
422 membrane-bound form(26). In our study, levels of sCD40L were elevated in NDM as  
423 compared to the T2DM patients indicating that the NDM patients may be undergoing an  
424 immuno suppressive reaction, as elevated sCD40L is also associated to immunosuppression.  
425 GRO (CXCL1) is a chemokine that attracts variety of immune cells, particularly neutrophils  
426 and is also implicated in wound healing process(27). Similar to sCD40L levels, GRO levels  
427 were also higher in NDM as compared to T2DM patients indicating that both inflammation  
428 and healing were occurring simultaneously in these patients. However, the healing mechanism  
429 was definitely poorer in T2DM patients. The levels of Macrophage-derived chemokine  
430 (MDC/CCL2) were also higher in NDM patients than T2DM patients. As MDC is known to  
431 be elevated in lung inflammation and hemorrhage but reduced in T2DM symptomatic patients,  
432 this is also suggesting towards a possible immunosuppressive function of MDC in this  
433 population(28).

434 To understand how different antibody isotypes influence the clinical phenotype in  
435 T2DM and NDM patients, we did an antibody isotyping from the plasma of these patients.  
436 Here, we found significant difference in the levels of IgA, IgM, IgG1, IgG2 and IgE between  
437 the two groups but IgG3 and IgG4 did not show any significant difference and we understand  
438 that the structure and function of different antibody isotypes vary from one another. For  
439 example, IgG1, IgG2 and IgG3 can fix complement(29). However, IgG4 cannot fix  
440 complement and is unable to induce antibody mediated cell cytotoxicity (ADCC). Similar to  
441 previous reports, we found an increase in the levels of IgE in T2DM patients(8, 16). This  
442 corroborated with the increase in the Th2 subset along with increase in cytokines, IL-4 and IL-  
443 9 in T2DM patients, as it is known that IgE is associated with Type II response. In addition,  
444 there was also an increase in IgG1 and IgG2 in these patients, indicative of the inflammatory  
445 response. However, as IgE was high in these T2DM patients, we could see no significant  
446 difference in IgG4 levels. This could be accredited to the competition between IgE and IgG4  
447 against each other, for fixation sites in basophils and mast cells, as suggested by previous  
448 reports(30). IgA levels were also found to be higher in T2DM, indicating towards viral immune  
449 response at mucosal surfaces(31). With respect to IgM, its increased levels indicate towards  
450 an ongoing infection. However, the lack of any longitudinal profiling restricts us from  
451 understanding its specificity to antigen(32).



452 With respect to our whole blood analysis by mass cytometry, we found an increase in  
453 the percentage of granulocytes in T2DM patients when compared to healthy controls indicating  
454 underlying inflammatory responses in these patients. This is consistent with other reports  
455 which suggested an increase in granulocytes with increasing severity(15, 33). On the other  
456 hand, we found a decreasing percentage of monocytes in T2DM patients as compared to NDM  
457 patients (**Table 1**), although the difference was not significant. This has also been reported in  
458 a previous study showing the absence of any significant changes in the total monocytes and its  
459 subsets in T2DM patients with various comorbidities, T2DM being one of them(15).  
460 Additionally, we also found that T2DM patients showed a decreasing trend in lymphocyte  
461 percentage as compared to NDM and healthy volunteers, as reported in previous studies (4, 8,  
462 15). One of the significant findings from our study is that, there is a drastic reduction in the  
463 percentage of total dendritic cells in T2DM patients when compared to both, NDM and healthy  
464 controls. Within the dendritic cell compartments, there is a decrease of pDCs but mDCs have  
465 increased in T2DM patients when compared with healthy controls. In general, pDCs are known  
466 to secrete type I interferons in response to viral infection(34). However, our study has shown  
467 a decrease in the percentage of pDCs, but increase in the cytokine IFN- $\alpha$ 2. This is suggesting  
468 that although these cells are secreting high levels of type I interferon, their numbers are depleted  
469 in T2DM patients and thus, are unable to control the infection. With respect to mDCs, they are  
470 known to secrete the cytokines IL-12 and TNF- $\alpha$ , which polarizes the T cell towards a type I  
471 response, crucial for controlling the viruses(35, 36). Our study also observed an increase in  
472 the population of mDCs along with increase in the cytokines, IL-12p40, TNF- $\alpha$  in T2DM.  
473 Although certain reports have suggested a decrease of mDCs along with pDCs, we observed  
474 the presence of high numbers of mDCs in diabetic patients, indicating an ongoing low grade  
475 inflammation, which is further augmented with Covid-19 infection. However, since we did  
476 not do a longitudinal profiling, we could not delineate the mDC dynamics in these patients(37,  
477 38).

478 With respect to basophils, literature suggested a decrease in its population with  
479 increasing severity(39). We found a similar trend, as the basophil population decreased in  
480 T2DM patients as compared to healthy controls. Similarly, MAIT/iNKT cells were  
481 significantly decreased in T2DM patients as compared to NDM and healthy controls.  
482 However, no significant differences were observed in the percentage of gamma delta T cells.  
483 A decrease in MAIT/iNKT could indicate towards a migration to other inflamed tissues  
484 including the lungs, as suggested by the previous reports. With respect to NK cell population,

485 it is known that they play a crucial role in fighting viral infections and previous reports  
486 suggested a decrease in their numbers in T2DM cases. However, our population of study did  
487 not show any significant difference amongst the groups and as mentioned earlier may be a  
488 consequence of the time of sampling of patients(40, 41).

489 In case of B cells, we observed a slight elevation in its percentage in T2DM patients,  
490 when compared to NDM and healthy controls, but statistical difference was found only  
491 between T2DM patients and healthy volunteers. Although no difference was observed in naive  
492 or memory B cell compartment, plasmablasts were significantly elevated in T2DM patients as  
493 compared to healthy controls. The increase in plasmablasts in T2DM Covid-19 has also been  
494 reported in other studies (8, 15)but unlike our study, they could not correlate it with any  
495 comorbidity. Interestingly, there are reports suggesting an increase in extrafollicular B cell  
496 response in Covid-19 and other inflammatory diseases such as Systemic Lupus Erythematosus.  
497 Since most of the Covid-19 patients had type II diabetes in our study, we hypothesize that these  
498 two factors might have augmented the plasmablast production. Although we did not analyze  
499 the clonality of B cells, but earlier study has suggested an oligoclonal expansion of B cells in  
500 T2DM Covid-19, in turn correlating with increased plasmablast production. Increased B cell  
501 population in T2DM patients also corroborated with the fact that most of the immunoglobulins  
502 (IgM, IgA, IgG and IgE) were elevated in these patients as opposed to NDM and healthy  
503 volunteers. Altogether, we found an increase in the plasmablast population in T2DM as  
504 compared to NDM patients and healthy volunteers, suggesting that the low grade inflammation  
505 in Diabetic patients resulted in increase in plasmablast population, which augmented further  
506 with Covid-19 infection in these patients.

507 T2DM patients also displayed a lower percentage of CD45<sup>+</sup>CD3<sup>+</sup> T cells as compared  
508 to healthy controls. Within CD3<sup>+</sup> T cell population, there was a decrease in the percentage of  
509 CD8<sup>+</sup> T cells in T2DM as compared to healthy volunteers. However, CD4<sup>+</sup> T cells did not  
510 show any statistically significant difference amongst the groups. Earlier reports have suggested  
511 the loss of CD8<sup>+</sup> T cells being greater than CD4<sup>+</sup> T cells. Since our population of study was  
512 small with heterogenous manifestation, this could explain why CD4<sup>+</sup> T cells did not show any  
513 difference amongst the groups. Additionally, several reports indicate towards T cell apoptosis  
514 or migration to other tissues in SAR-CoV2 infection, leading to decrease in T cell population  
515 in the periphery and could account for the decrease in T cells in the T2DM patients(42-44). In  
516 general, there was decrease in the CD3<sup>+</sup> T cell population, where the CD8<sup>+</sup> compartment was  
517 affected more significantly than CD4<sup>+</sup>.

518 Type II diabetes has been reported to have various aberrancies such as an impaired  
519 differential potential and secretion of multiple proinflammatory cytokines such as TNF- $\alpha$  and  
520 IFN- $\gamma$ (37, 45). Although we could not find any significant difference amongst the groups in  
521 the percentage of Th1 like, Th17 like, Treg or cTfh subtypes, there was an increase in the  
522 proinflammatory cytokines. We understand that the absence of difference amongst the groups  
523 with respect to T cell subsets can be accounted to the time of sampling. On the other hand, our  
524 study found an increase in the percentage of Th2 cells secreting type II cytokines such as IL-4  
525 and IL-9. The high numbers of Th2 cells partially explained the augmented levels of  
526 immunoglobulins in these patients, specifically IgE which is induced by cytokines such as IL-  
527 4. Taken together, this indicated that the Diabetic patients already had low grade inflammation.  
528 When encountered with Covid-19, dysregulation in the immune system escalated to such levels  
529 that even with the increase in Th2 population secreting anti-inflammatory cytokines,  
530 inflammation could not subdue.

531 We also analyzed for the naïve, effector and memory compartments in both CD4<sup>+</sup> and  
532 CD8<sup>+</sup> T cells. In CD4<sup>+</sup> T cells, we did not see any difference in the overall percentage of naive  
533 (CCR7<sup>+</sup>CD45RA<sup>+</sup>CD45RO<sup>-</sup>) and central memory cells (CCR7<sup>+</sup>CD45RA<sup>-</sup>CD45RO<sup>+</sup>) amongst  
534 the various groups. However, effector memory cells (CCR7<sup>-</sup>CD45RA<sup>-</sup>CD45RO<sup>+</sup>CD27<sup>+</sup>) were  
535 elevated in T2DM patients when compared to healthy controls, suggesting cross reactivity with  
536 other family of coronavirus, as reported by a previous study from India(46, 47). An important  
537 point to note here is that central memory cells did not show any significant difference and this  
538 may be due to the fact that CM cells are lymph node residents as opposed to EM cells, which  
539 circulate in blood and thus, respond faster to the antigen (data not shown). However, since we  
540 did not analyze for the antigen specific cells, therefore we were unable to find any significant  
541 difference in the percentage of CM cells. Terminal effector (CCR7<sup>-</sup>CD45RA<sup>-</sup>CD45RO<sup>+</sup>CD27<sup>-</sup>  
542 ) cells were decreased in T2DM patients with Covid-19 as compared to healthy controls,  
543 corroborating with the observation that these cells are first to react with the virus and the  
544 subsequent proinflammatory cytokine milieu is responsible for the apoptosis of these cells.

545 In CD8<sup>+</sup> T cell compartment, EM (CCR7<sup>-</sup>CD27<sup>+</sup>) cells were elevated in NDM as  
546 compared to T2DM patients, indicating an effective immune response in these patients but less  
547 effective in T2DM patients. TE (CCR7<sup>-</sup>CD27<sup>-</sup>) cells increased in T2DM patients indicating  
548 that these cells are highly inflammatory and might be insensitive to AICD (47-49).

549           Altogether, our data suggests that Meta inflammation present in these T2DM patients  
550 is responsible for aggravation of the inflammation occurring due to Covid-19. With T2DM  
551 being one of the most common morbidity presents in India, these patients remain most  
552 vulnerable and were susceptible to secondary infections like mucormycosis. Though  
553 vaccinations are lowering the severity of the disease, reported waning antibody response in 3-  
554 6 months is a major concern apart from how long the protective immunity from T cells will  
555 work in these patients is also yet to be ascertained. Our study is essentially aimed at  
556 understanding how a low grade chronic inflammatory disorder such as Type II Diabetes  
557 dictates the immune response during the pathogenesis of Covid-19. We understand that our  
558 study is not devoid of limitations such as a small sample size, absence of longitudinal study or  
559 follow up, but nevertheless it will help in understanding the vulnerability of these patients and  
560 subsequent planning of vaccine coverage in these patients or future vaccines booster dosages  
561 to them.

## 562 **References**

563

- 564 1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and  
565 pathogenesis. *J Med Virol.* 2020;92(10):2249.
- 566 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019  
567 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506.
- 568 3. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med.* 2020;383(25):2451-60.
- 569 4. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients  
570 With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis.* 2020;71(15):762-8.
- 571 5. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. *J Thromb Haemost.*  
572 2020;18(9):2103-9.
- 573 6. Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-  
574 mediated effector immunity. *J Allergy Clin Immunol.* 2015;135(3):626-35.
- 575 7. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+  
576 T cells. *Science.* 2010;327(5969):1098-102.
- 577 8. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal  
578 immunological misfiring in severe COVID-19. *Nature.* 2020;584(7821):463-9.
- 579 9. Chatterjee S, Datey A, Sengupta S, Ghosh A, Jha A, Walia S, et al. 2021.
- 580 10. Jogdand GM, Sengupta S, Bhattacharya G, Singh SK, Barik PK, Devadas S. Inducible  
581 Costimulator Expressing T Cells Promote Parasitic Growth During Blood Stage Plasmodium berghei  
582 ANKA Infection. *Front Immunol.* 2018;9:1041.
- 583 11. Prodjinotho UF, von Horn C, Debrah AY, Batsa Debrah L, Albers A, Layland LE, et al.  
584 Pathological manifestations in lymphatic filariasis correlate with lack of inhibitory properties of IgG4  
585 antibodies on IgE-activated granulocytes. *PLoS Negl Trop Dis.* 2017;11(7):e0005777.
- 586 12. Bagwell CB, Hunsberger B, Hill B, Herbert D, Bray C, Selvanantham T, et al. Multi-site  
587 reproducibility of a human immunophenotyping assay in whole blood and peripheral blood  
588 mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an  
589 automated data analysis system. *Cytometry B Clin Cytom.* 2020;98(2):146-60.

- 590 13. Geanon D, Lee B, Gonzalez-Kozlova E, Kelly G, Handler D, Upadhyaya B, et al. A streamlined  
591 whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19. *Cytometry A*.  
592 2021;99(5):446-61.
- 593 14. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation  
594 and intervention. *Nat Rev Immunol*. 2020;20(6):363-74.
- 595 15. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, et al.  
596 Comprehensive mapping of immune perturbations associated with severe COVID-19. *Sci Immunol*.  
597 2020;5(49).
- 598 16. Zhao R, Sun Y, Zhang Y, Wang W, Wang S, Wang C, et al. Distinguishable Immunologic  
599 Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with Nondiabetic  
600 Individuals. *Mediators Inflamm*. 2020;2020:6914878.
- 601 17. Sohn Y, Jeong SJ, Chung WS, Hyun JH, Baek YJ, Cho Y, et al. Assessing Viral Shedding and  
602 Infectivity of Asymptomatic or Mildly Symptomatic Patients with COVID-19 in a Later Phase. *J Clin*  
603 *Med*. 2020;9(9).
- 604 18. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper  
605 Respiratory Specimens of Infected Patients. *N Engl J Med*. 2020;382(12):1177-9.
- 606 19. Li G, Chen Z, Lv Z, Li H, Chang D, Lu J. Diabetes Mellitus and COVID-19: Associations and  
607 Possible Mechanisms. *Int J Endocrinol*. 2021;2021:7394378.
- 608 20. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-  
609 associated diseases in organs. *Oncotarget*. 2018;9(6):7204-18.
- 610 21. Yaribeygi H, Sathyapalan T, Jamialahmadi T, Sahebkar A. The Impact of Diabetes Mellitus in  
611 COVID-19: A Mechanistic Review of Molecular Interactions. *J Diabetes Res*. 2020;2020:5436832.
- 612 22. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression  
613 and prognosis of COVID-19. *Diabetes Metab Res Rev*. 2020:e3319.
- 614 23. Ozsurekci Y, Aykac K, Er AG, Halacli B, Arasli M, Oygur PD, et al. Predictive value of  
615 cytokine/chemokine responses for the disease severity and management in children and adult cases  
616 with COVID-19. *J Med Virol*. 2021;93(5):2828-37.
- 617 24. Verbist KC, Klonowski KD. Functions of IL-15 in anti-viral immunity: multiplicity and variety.  
618 *Cytokine*. 2012;59(3):467-78.
- 619 25. Tani-ichi S, Shimba A, Wagatsuma K, Miyachi H, Kitano S, Imai K, et al. Interleukin-7 receptor  
620 controls development and maturation of late stages of thymocyte subpopulations. *Proc Natl Acad Sci*  
621 *U S A*. 2013;110(2):612-7.
- 622 26. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, et al. Elevated serum soluble CD40  
623 ligand in cancer patients may play an immunosuppressive role. *Blood*. 2012;120(15):3030-8.
- 624 27. Zaja-Milatovic S, Richmond A. CXC chemokines and their receptors: a case for a significant  
625 biological role in cutaneous wound healing. *Histol Histopathol*. 2008;23(11):1399-407.
- 626 28. Richter JR, Sutton JM, Belizaire RM, Friend LA, Schuster RM, Johannigman TA, et al.  
627 Macrophage-derived chemokine (CCL22) is a novel mediator of lung inflammation following  
628 hemorrhage and resuscitation. *Shock*. 2014;42(6):525-31.
- 629 29. van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4  
630 antibodies. *Clin Exp Immunol*. 1986;64(2):415-22.
- 631 30. Dodev TS, Bowen H, Shamji MH, Bax HJ, Beavil AJ, McDonnell JM, et al. Inhibition of allergen-  
632 dependent IgE activity by antibodies of the same specificity but different class. *Allergy*.  
633 2015;70(6):720-4.
- 634 31. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the early  
635 neutralizing antibody response to SARS-CoV-2. *Sci Transl Med*. 2021;13(577).
- 636 32. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in  
637 Patients With Novel Coronavirus Disease 2019. *Clin Infect Dis*. 2020;71(16):2027-34.
- 638 33. Vitte J, Diallo AB, Boumaza A, Lopez A, Michel M, Allardet-Servent J, et al. A Granulocytic  
639 Signature Identifies COVID-19 and Its Severity. *J Infect Dis*. 2020;222(12):1985-96.

- 640 34. Cervantes-Barragan L, Zust R, Weber F, Spiegel M, Lang KS, Akira S, et al. Control of  
641 coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. *Blood*.  
642 2007;109(3):1131-7.
- 643 35. van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, et al. Functional  
644 impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.  
645 *Hepatology*. 2004;40(3):738-46.
- 646 36. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation,  
647 and protection of dendritic cells induced by double-stranded RNA. *J Exp Med*. 1999;189(5):821-9.
- 648 37. Yao K, Lu H, Huang R, Zhang S, Hong X, Shi H, et al. Changes of dendritic cells and fractalkine  
649 in type 2 diabetic patients with unstable angina pectoris: a preliminary report. *Cardiovasc Diabetol*.  
650 2011;10:50.
- 651 38. Sun Y, Zhou J, Ye K. White Blood Cells and Severe COVID-19: A Mendelian Randomization  
652 Study. *J Pers Med*. 2021;11(3).
- 653 39. Jouan Y, Guillon A, Gonzalez L, Perez Y, Boisseau C, Ehrmann S, et al. Phenotypical and  
654 functional alteration of unconventional T cells in severe COVID-19 patients. *J Exp Med*. 2020;217(12).
- 655 40. Parrot T, Gorin JB, Ponzetta A, Maleki KT, Kammann T, Emgard J, et al. MAIT cell activation  
656 and dynamics associated with COVID-19 disease severity. *Sci Immunol*. 2020;5(51).
- 657 41. Zhai X, Qian G, Wang Y, Chen X, Lu J, Zhang Y, et al. Elevated B Cell Activation is Associated  
658 with Type 2 Diabetes Development in Obese Subjects. *Cell Physiol Biochem*. 2016;38(3):1257-66.
- 659 42. Shrotri M, van Schalkwyk MCI, Post N, Eddy D, Huntley C, Leeman D, et al. T cell response to  
660 SARS-CoV-2 infection in humans: A systematic review. *PLoS One*. 2021;16(1):e0245532.
- 661 43. Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. Impaired immune cell  
662 cytotoxicity in severe COVID-19 is IL-6 dependent. *J Clin Invest*. 2020;130(9):4694-703.
- 663 44. Gil-Etayo FJ, Suarez-Fernandez P, Cabrera-Marante O, Arroyo D, Garcinuno S, Naranjo L, et al.  
664 T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. *Front Cell Infect*  
665 *Microbiol*. 2021;11:624483.
- 666 45. Ansari A, Arya R, Sachan S, Jha SN, Kalia A, Lall A, et al. Immune Memory in Mild COVID-19  
667 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection. *Front*  
668 *Immunol*. 2021;12:636768.
- 669 46. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to  
670 SARS-CoV-2. *Nat Rev Immunol*. 2020;20(11):709-13.
- 671 47. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to  
672 infection. *Annu Rev Immunol*. 2000;18:275-308.
- 673 48. Reiser J, Banerjee A. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor  
674 Immune Response. *J Immunol Res*. 2016;2016:8941260.
- 675 49. Martin MD, Badovinac VP. Defining Memory CD8 T Cell. *Front Immunol*. 2018;9:2692.


676

677

678


679

680




**Fig 1. Analysis of Viral load in Oropharyngeal samples in Covid-19 patients.**(A) Bar diagram depicting the viral copy number of Oropharyngeal (OP) samples collected from T2DM(n=25) and NDM(n=10) COVID-19 patients.(B) Bar diagram representing the  $\Delta\Delta$  Ct of OP samples of NDM and T2DM COVID-19 patients. The Mann-Whitney (non parametric, two tailed) test was performed. ns, not significant. All error bars were SEM.

681



**Fig 2. Analysis of the cytokines and chemokines in T2DM, NDM patients infected with SARS-CoV2**  
The bar diagrams representing cytokines and chemokines which were evaluated from COVID-19 positive plasma samples of T2DM(n=25), NDM(n=10) and Covid-19 negative and non-diabetic healthy controls(n=10). (A) IL-6, TNF- $\alpha$ , GCSF, IL-12p40, IL-15, IL-1 $\alpha$ , MIP-1 $\beta$ , GM-CSF, IFN- $\alpha$ 2, IL-10, VEGF and IL-18 were highly elevated in T2DM patients when compared with healthy controls and NDM patients. (B) IFN- $\gamma$ , EGF and IL-8 were moderately elevated in T2DM patients when compared to healthy controls and NDM. (C) IP-10, IL-9 and IL-4 were slightly elevated in T2DM patients when compared to healthy controls and NDM. (D) Eotaxin was moderately elevated in healthy controls and NDM when compared to T2DM patients. (E) sCD40L was elevated in both NDM and T2DM when compared to healthy controls, MDC was elevated in NDM patients when compared to T2DM patients. (F) GRO was elevated in NDM patients when compared to healthy controls. The Kruskal Wallis Test (non parametric) with post hoc Dunn's multiple comparison test was performed  $p < 0.05$  was considered statistically significant (\*),  $p < 0.01$  was considered to be very significant (\*\*),  $P < 0.001$  was considered to be highly significant(\*\*\*),  $P < 0.0001$  was considered extremely significant(\*\*\*\*) ns, not significant. All error bars were SEM.


682



**Fig 3. Analysis of the circulating antibodies in T2DM, NDM patients infected with SARS-CoV2**

The bar diagram representing circulating antibody isotypes (IgA, IgM, IgG1, IgG2, IgG3, IgG4 and IgE) which were evaluated from COVID-19 positive plasma samples of T2DM (n=25), NDM (n=10) and Covid-19 negative and non-diabetic healthy controls (n=10). The Kruskal Wallis Test (non parametric) with post hoc Dunn's multiple comparison test was performed.  $p < 0.05$  was considered statistically significant (\*),  $p < 0.01$  was considered to be very significant (\*\*),  $p < 0.001$  was considered to be highly significant (\*\*\*),  $p < 0.0001$  was considered extremely significant (\*\*\*\*), ns, not significant. All error bars were SEM.

683




**Fig 4. Innate Immune Cells in T2DM and NDM patients.** Whole blood from Covid-19 positive T2DM (n=10), NDM (n=5) and Covid-19 negative and non-diabetic healthy controls (n=5) was stained heavy metal tagged antibody and analyzed in mass cytometer. (A) Representative Gating strategy to identify CD45<sup>+</sup>CD66b<sup>int</sup> lymphocytes and CD45<sup>+</sup>CD66b<sup>high</sup> Granulocytes. Statistical analysis of percentage of Granulocytes and lymphocytes. (B) Gating strategy for CD11c<sup>+</sup> pDCs. Statistical analysis for the frequency of total DCs and pDCs. (C) Gating strategy for CD11c<sup>+</sup>CD38<sup>+</sup> mDCs. Statistical analysis for the percentage of mDCs. (D) Gating strategy for CD123<sup>+</sup>CD294<sup>+</sup> Basophils. Statistical analysis for the frequency of basophils. (E) Gating strategy for MAIT/NKT cells. Statistical analysis for the frequency of MAIT/NKT cells. The Kruskal Wallis Test (non parametric) with post hoc Dunn's multiple comparison test was performed.  $p < 0.05$  was considered statistically significant (\*),  $p < 0.01$  was considered to be very significant (\*\*),  $p < 0.001$  was considered to be highly significant (\*\*\*),  $p < 0.0001$  was considered extremely significant (\*\*\*\*), ns, not significant. All error bars were SEM.

684

685

686






**Fig 5. Adaptive Immune Cells in T2DM and NDM patients.** Whole blood from Covid-19 positive T2DM (n=10), NDM (n=5) and Covid-19 negative and non-diabetic healthy controls (n=5) was stained heavy metal tagged antibody and analyzed in mass cytometer. (A) Representative Gating strategy to identify CD38<sup>+</sup>CD20<sup>+</sup> Plasmablasts. (B) Gating strategy to identify CD45<sup>+</sup>CD3<sup>+</sup>CD4<sup>+</sup> and CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> T cells. Statistical analysis for the frequency of CD3<sup>+</sup>CD4<sup>+</sup> and CD8<sup>+</sup> T cells. (C) Gating strategy for CD4<sup>+</sup>CXCR5<sup>+</sup>CCR6<sup>+</sup>Th2 like cells. Statistical analysis for the percentage of Th2 like cells. (D) Gating strategy to identify CD4<sup>+</sup>TE (CD45RO<sup>+</sup>CD27<sup>+</sup>) and CD4<sup>+</sup>EM cells (CD45RO<sup>+</sup>CD27<sup>+</sup>). Statistical analysis for the percentages of CD4<sup>+</sup>TE and EM cells. (E) Gating strategy to identify CD8<sup>+</sup>TE (CCR7<sup>+</sup>CD27<sup>+</sup>) and EM (CCR7<sup>+</sup>CD27<sup>+</sup>) cells. Statistical analysis for the percentages of the CD8<sup>+</sup>TE and EM cells. The Kruskal Wallis Test (non parametric) with post hoc Dunn's multiple comparison test was performed.  $p < 0.05$  was considered statistically significant (\*),  $p < 0.01$  was considered to be very significant (\*\*),  $P < 0.001$  was considered to be highly significant (\*\*\*),  $P < 0.0001$  was considered extremely significant (\*\*\*\*), ns, not significant. All error bars were SEM.

687

688



**Fig.6 t-SNE analysis of lowest and highest expressed markers in T2DM patients. (A) CD8 and CD3 showing decreased expression in T2DM patients. (B) HLA-DR and CD 14 showing increased expression in T2DM patients when compared to controls.**

689

690

691

**Table 1- Demographic details and laboratory findings of T2DM and NDM patients infected with SARS-CoV2**

	T2DM n=25	NDM n=10	P VALUE
Age, median (IQR), years	46 (36-59)	49(40.25-55.50)	N. A
Sex, male/female, n (%)	17 (68%)/8(32%)	7 (70%)/3(10%)	N. A
Haemoglobin, gm/dl median (IQR)	12.2 (11.35-13.60)	14.25 (13.7-14.9)	0.0475
Platelets 10 <sup>3</sup> /μL median (IQR)	193 (154.5-235)	165 (159.5-197.5)	0.4027
White Blood Cells 10 <sup>3</sup> /μL, median (IQR)	6.1 (5.00-57.65)	5.8 (5.2-5.575)	0.4172
Neutrophils %, median (IQR)	75 (65.5-84)	55 (44.75-62)	0.0004
Lymphocytes%, median (IQR)	22 (15.5-29.75)	36 (26.75-39.75)	0.0349
Eosinophils %, median (IQR)	0	3 (3-4.5)	<0.0001
Monocytes%, median (IQR)	7 (5-9)	9 (8.5-10)	0.0373
D-dimer μg/mL, median (IQR)	0.45 (0.29-1.61)	0.19 (0.15-0.25)	0.0048
Ferritin ng/mL, median (IQR)	224.7 (145.9-464.1)	115 (110-289.5)	0.4975
Fasting Plasma Glucose mg/dL, median (IQR)	215 (142.72-244)	95.5 (88-101)	<0.0001
Hb1AC %, median (IQR)	6.9 (6-9)	N. T	N. A
CRP mg/mL, median (IQR)	69.62 (34.95-211)	13.28 (4.44-18.65)	0.0013
Serum SGOT U/L, median (IQR)	46.9 (30.2-64.6)	38 (30.75-43.25)	0.4432
Serum SGPT U/L, median (IQR)	27.6 (20-42)	40.5 (24.5-76.5)	0.1335

**Hb1AC- Glycated haemoglobin, CRP- C-Reactive Protein, Serum SGOT-serum glutamic-oxaloacetic transaminase, Serum SGPT- serum glutamic-pyruvic transaminase, N.T-Not Tested, N.A-Not Applicable.**